Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free UPC Stock Alerts

Universe Pharmaceuticals (UPC) Competitors

Universe Pharmaceuticals logo
$6.24 +0.08 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$6.26 +0.02 (+0.34%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

UPC vs. MTVA, GELS, TRAW, ADXN, and PCSA

Should you buy Universe Pharmaceuticals stock or one of its competitors? MarketBeat compares Universe Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Universe Pharmaceuticals include MetaVia (MTVA), Gelteq (GELS), Traws Pharma (TRAW), Addex Therapeutics (ADXN), and Heatwurx (PCSA).

How does Universe Pharmaceuticals compare to MetaVia?

Universe Pharmaceuticals (NASDAQ:UPC) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,279.31%. Given MetaVia's stronger consensus rating and higher probable upside, analysts clearly believe MetaVia is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MetaVia
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Universe Pharmaceuticals' return on equity of 0.00% beat MetaVia's return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
MetaVia N/A -172.92%-89.39%

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MetaVia had 3 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for MetaVia and 0 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.00 equaled MetaVia'saverage media sentiment score.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
MetaVia Neutral

Universe Pharmaceuticals has higher revenue and earnings than MetaVia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.74M0.20-$3.67MN/AN/A
MetaViaN/AN/A-$12.97M-$5.19N/A

Universe Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Summary

Universe Pharmaceuticals beats MetaVia on 6 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Gelteq?

Gelteq (NASDAQ:GELS) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Universe Pharmaceuticals has higher revenue and earnings than Gelteq.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gelteq$165.65K37.12-$4.30MN/AN/A
Universe Pharmaceuticals$17.74M0.20-$3.67MN/AN/A

0.2% of Universe Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
GelteqN/A N/A N/A
Universe Pharmaceuticals N/A N/A N/A

In the previous week, Gelteq's average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Gelteq Neutral
Universe Pharmaceuticals Neutral

Gelteq has a beta of -0.45, meaning that its stock price is 145% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gelteq
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Universe Pharmaceuticals beats Gelteq on 5 of the 6 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Traws Pharma has higher earnings, but lower revenue than Universe Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$2.79M2.93$9.17M-$1.69N/A
Universe Pharmaceuticals$17.74M0.20-$3.67MN/AN/A

Traws Pharma currently has a consensus price target of $1.00, indicating a potential upside of 85.53%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Traws Pharma is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 7.6% of Traws Pharma shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws PharmaN/A -913.18% -133.88%
Universe Pharmaceuticals N/A N/A N/A

In the previous week, Traws Pharma had 3 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for Traws Pharma and 0 mentions for Universe Pharmaceuticals. Traws Pharma's average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Traws Pharma Neutral
Universe Pharmaceuticals Neutral

Traws Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Summary

Traws Pharma beats Universe Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -134.76% -106.00%
Universe Pharmaceuticals N/A N/A N/A

Addex Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Addex Therapeutics Neutral
Universe Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Universe Pharmaceuticals has higher revenue and earnings than Addex Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$29.97K232.65-$8.12M-$5.94N/A
Universe Pharmaceuticals$17.74M0.20-$3.67MN/AN/A

Summary

Universe Pharmaceuticals beats Addex Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Heatwurx?

Universe Pharmaceuticals (NASDAQ:UPC) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Universe Pharmaceuticals' return on equity of 0.00% beat Heatwurx's return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Heatwurx N/A -281.31%-200.80%

In the previous week, Heatwurx's average media sentiment score of 0.42 beat Universe Pharmaceuticals' score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
Heatwurx Neutral

Universe Pharmaceuticals has higher revenue and earnings than Heatwurx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.74M0.20-$3.67MN/AN/A
HeatwurxN/AN/A-$13.56M-$9.29N/A

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Heatwurx has a consensus target price of $25.00, indicating a potential upside of 986.96%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts plainly believe Heatwurx is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Heatwurx
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Universe Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Heatwurx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Summary

Universe Pharmaceuticals beats Heatwurx on 6 of the 11 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPC vs. The Competition

Export
MetricUniverse PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.51M$11.79B$6.93B$12.84B
Dividend YieldN/A2.73%2.60%9.78%
P/E RatioN/A794.01281.1625.43
Price / Sales0.20746.53576.6582.30
Price / CashN/A72.4271.7950.79
Price / Book0.0610.7312.866.06
Net Income-$3.67M$2.82B$3.49B$348.34M
7 Day Performance79.31%2.88%2.65%3.03%
1 Month Performance4.00%-1.28%-2.63%-3.04%
1 Year Performance77.27%195.94%76.00%20.65%

Universe Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPC
Universe Pharmaceuticals
0.6001 of 5 stars		$6.24
+1.3%		N/A+71.6%$3.51M$17.74MN/A220
MTVA
MetaVia
1.583 of 5 stars		$1.45
-2.0%		$20.00
+1,279.3%		-77.4%$7.64MN/AN/A8
GELS
Gelteq
N/A$0.66
-5.7%		N/A-66.0%$7.51M$165.65KN/AN/A
TRAW
Traws Pharma
2.5873 of 5 stars		$0.52
+6.5%		$1.00
+92.3%		-63.8%$7.39M$2.79MN/A17
ADXN
Addex Therapeutics
0.6031 of 5 stars		$5.84
-0.8%		N/A-38.7%$7.25M$29.97KN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Nvidia's CEO says this small device is critical for AI growth
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel